Sanofi led a $150m Series C round in Enveda.

Sanofi, a healthcare company, led a $150m Series C funding round in Enveda, a drug discovery and development company using the latest AI-powered technologies. "We believe that nature holds the key to the next generation of breakthrough medicines, and we are proving that in the clinic. This investment from a global leader in immunology, is a testament to the transformative potential of our platform, our team’s execution, and the growing realization that AI can radically unlock insight into the natural world to change lives. We have beat the industry’s pace and success rate of drug discovery, providing novel medicines that we hope fill the therapeutic gaps," Viswa Colluru, Enveda CEO & Founder.